KLDO (Kaleido Biosciences) Total Equity: $10.61 Mil (As of Dec. 2021)


What is Kaleido Biosciences Total Equity?

Kaleido Biosciences KLDO Total Equity is $10.61 Mil as of Dec. 2021.

Kaleido Biosciences's total equity for the quarter that ended in Dec. 2021 was $10.61 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Kaleido Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences Total Equity Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Equity
Get a 7-Day Free Trial -43.68 -96.24 48.88 20.50 10.61

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.50 71.77 50.27 29.20 10.61

Kaleido Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Kaleido Biosciences's Total Equity for the fiscal year that ended in Dec. 2021 is calculated as

Total Equity=Total Assets(Q: Dec. 2021 )-Total Liabilities(Q: Dec. 2021 )
=50.137-39.53
=10.61

Kaleido Biosciences's Total Equity for the quarter that ended in Dec. 2021 is calculated as

Total Equity=Total Assets(Q: Dec. 2021 )-Total Liabilities(Q: Dec. 2021 )
=50.137-39.53
=10.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $10.61 Mil mean?
Kaleido Biosciences (KLDO) has a Total Equity of $10.61 Mil as of Dec. 2021. The total amount of equity as record on a company's balance sheet. View historical data for Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' Total Equity too high?
Kaleido Biosciences' current Total Equity is $10.61 Mil.
How does Kaleido Biosciences' Total Equity compare to NPTX and GSTC?
Kaleido Biosciences' Total Equity of $10.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Kaleido Biosciences and its competitors. Kaleido Biosciences's current Total Equity is $10.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current Total Equity of $10.61 Mil. The current Total Equity is $10.61 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current Total Equity is $10.61 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.